# Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

> **NCT05953103** · PHASE2 · TERMINATED · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 80 (actual)

## Conditions studied

- Subjects With Cerebral Hemorrhage

## Interventions

- **DRUG:** Sanbexin IV/Placebo

## Key facts

- **NCT ID:** NCT05953103
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-03
- **Primary completion:** 2025-04-02
- **Final completion:** 2025-04-02
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** This study was terminated after completing the first dose level of Sanbenxin 37.5 mg due to the decision made by the sponsor that a new clinical development program for the new form of sublingual tablets would replace the existing plan.
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953103, "Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05953103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*